These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 11279651)
21. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123 [TBL] [Abstract][Full Text] [Related]
22. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949 [TBL] [Abstract][Full Text] [Related]
23. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566 [TBL] [Abstract][Full Text] [Related]
24. [The home treatment of deep venous thromboses with low-molecular-weight heparin]. Grau Segura E; Real Vila E; Pastor Guzmán E; Torró Richart JA; Garay Burdeos M Rev Clin Esp; 1997 Jun; 197(6):398-401. PubMed ID: 9304129 [TBL] [Abstract][Full Text] [Related]
25. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
26. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Couturaud F; Julian JA; Kearon C Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355 [TBL] [Abstract][Full Text] [Related]
27. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369 [TBL] [Abstract][Full Text] [Related]
28. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis]. Nielsen JD; Landorph A Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276 [TBL] [Abstract][Full Text] [Related]
29. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC; J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561 [TBL] [Abstract][Full Text] [Related]
30. Home-treatment of deep vein thrombosis in patients with cancer. Ageno W; Grimwood R; Limbiati S; Dentali F; Steidl L; Wells PS Haematologica; 2005 Feb; 90(2):220-4. PubMed ID: 15710575 [TBL] [Abstract][Full Text] [Related]
31. Anticoagulants in the treatment of deep vein thrombosis. Merli G Am J Med; 2005 Aug; 118 Suppl 8A():13S-20S. PubMed ID: 16125510 [TBL] [Abstract][Full Text] [Related]
32. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Robertson L; Jones LE Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249 [TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521 [TBL] [Abstract][Full Text] [Related]
35. Heparins and venous thromboembolism: current practice and future directions. Prandoni P Thromb Haemost; 2001 Jul; 86(1):488-98. PubMed ID: 11487039 [TBL] [Abstract][Full Text] [Related]
36. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Creekmore FM; Oderda GM; Pendleton RC; Brixner DI Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654 [TBL] [Abstract][Full Text] [Related]
38. Low molecular weight heparins: the optimal treatment for venous thromboembolism. Daskalopoulos ME; Daskalopoulou SS; Liapis CD Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244 [TBL] [Abstract][Full Text] [Related]
39. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S; Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872 [TBL] [Abstract][Full Text] [Related]
40. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group. van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]